Revised SPC: Actiq (fentanyl) Lozenges

Sleep apnoea syndrome has been added as a potential adverse effect of treatment (frequency unknown). SPC advises that opioid use increases the risk of central sleep apnoea (CSA) in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dose.

Source:

electronic Medicines compendium